publication date: Sep. 1, 2017

In Brief Guenther Koehne named chief of bone marrow transplantation and hematologic oncology at Miami Cancer Institute

Guenther Koehne was named chief of Bone Marrow Transplantation and Hematologic Oncology at Miami Cancer Institute, part of Baptist Health South Florida.

Koehne is a physicians in the Adult Bone Marrow Transplantation Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center. Miami Cancer Institute is a member of the Memorial Sloan Kettering Cancer Alliance.

“We are thrilled to welcome someone of Dr. Koehne’s stature to our team of experts,” said Michael Zinner, founding CEO and executive medical director of Miami Cancer Institute. “He will lead the development and growth of our bone marrow transplant program from its inception, delivering on the solution to a critical community health need. With a limited number of bone marrow transplant programs available in South Florida, our program – under Dr. Koehne’s uniquely qualified leadership – means fewer patients will need to leave the area to receive the care they need. His impact will be immediately felt.”

Koehne is an expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with autologous and allogeneic stem cell transplantations. He is known for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes in the treatment of viral complications following allogeneic transplants, and developed new approaches to the treatment … Continue reading Guenther Koehne named chief of bone marrow transplantation and hematologic oncology at Miami Cancer Institute

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.